Bristol Myers Squibb, Cobenfy
Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving revenue. Read my update on BMY stock.
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel treatment for schizophrenia. Bristol-Myers shares stood about 6% higher in recent premarket trading,
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the debilitating mental disorder in over seven decades.
Bristol Myers Squibb Vs. AbbVie Stock
Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – AbbVie stock .
FDA approves new Bristol Myers Squibb schizophrenia drug
Shares of Bristol Myers Squibb (BMY) are surging after the FDA approved the pharmaceutical giant's schizophrenia drug, making it the first new drug-related approach for the disease in 30 years. Morning Brief Hosts Seana Smith and Madison Mills report more on the story and dig into how the drug works.
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors
Shares of Bristol Myers Squibb Co. BMY slid 1.94% to $49.95 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.19% to 5,722.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure showed that consumer prices continue to ...
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
devdiscourse1h
Bristol Myers' Breakthrough Schizophrenia Drug Secures FDA Approval
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...
Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use
An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...